Highlight
- Ovarian immature teratomas (IT) with microscopic yolk sac tumor (YST) occur in approximately 11% of cases in children and adolescents.
- Patients with microscopic YST present with higher tumor grade, stage, and elevated alpha fetoprotein levels at diagnosis compared to IT without YST.
- Despite adverse pathological features, recurrence-free survival (RFS) does not significantly differ between those with and without microscopic YST.
- Treatment regimens often include chemotherapy for microscopic YST, which may impact recurrence outcomes, highlighting the need for standardized management guidelines.
Study Background
Immature teratoma (IT) of the ovary is a rare germ cell tumor predominantly affecting children and adolescents. IT tumors are characterized histologically by immature neuroectodermal tissue and can vary widely in biological behavior. Management of ovarian IT is challenging due to its rarity and heterogeneous clinical course, with controversies surrounding the role of adjuvant chemotherapy especially in early-stage disease. A further complexity arises with the presence of yolk sac tumor (YST) components within IT. YST is a malignant germ cell tumor known for aggressive behavior and elevation of serum alpha fetoprotein (AFP). However, when YST exists only as microscopic foci within ovarian IT (<5% of the tumor or a single microscopic focus), the clinical and prognostic significance remains unclear. This ambiguity complicates treatment decisions regarding aggressiveness of therapy. The study aimed to elucidate the clinical features, treatment patterns, and outcomes specifically in pediatric and adolescent patients with ovarian IT that contain microscopic YST foci, compared against those without YST, to inform clinical management and risk stratification strategies.
Study Design
This was a multicenter retrospective review involving 29 institutions coordinated by the Pediatric Surgical Oncology Research Collaborative. The cohort comprised females younger than 18 years diagnosed with ovarian immature teratoma between 2010 and 2022. The pathological assessment focused on identifying microscopic YST foci, defined as 5% or less of tumor volume or singular microscopic foci as documented by institutional pathologists. Patients were stratified into two groups: those with microscopic YST and those without. Clinical variables collected included tumor grade, stage (based on standard ovarian cancer staging), serum AFP levels at diagnosis, treatment modalities, and follow-up data including recurrence and survival outcomes. The primary endpoint was recurrence-free survival (RFS), with secondary endpoints comprising treatment patterns and overall recurrence rates. Statistical analyses compared characteristics and outcomes between groups to determine the prognostic relevance of microscopic YST presence.
Key Findings
The cohort comprised 143 pediatric and adolescent patients with ovarian immature teratoma, of which 16 (11.1%) harbored microscopic foci of yolk sac tumor. Key observations included:
- Clinical and Pathological Characteristics: The microscopic YST group exhibited significantly higher tumor grade and advanced stage at diagnosis relative to those without microscopic YST. These patients also had elevated alpha fetoprotein levels, consistent with the known biology of yolk sac tumors.
- Treatment Patterns: Chemotherapy administration was notably more frequent in patients with microscopic YST (68.8%) compared to the non-YST group. Surgical approaches were similar between groups, emphasizing adjuvant chemotherapy as a key differentiating treatment component.
- Recurrence and Survival Outcomes: During follow-up, three patients (18.8%) in the YST group experienced recurrence—two malignant and one mature teratoma recurrence. The overall recurrence rate was 6.25% for malignant recurrence in the YST group versus 7.1% in those without microscopic YST, a difference that was not statistically significant. Recurrence-free survival curves showed no significant difference between groups, suggesting similar prognostic trajectories despite more adverse baseline features in the microscopic YST cohort.
- Interpretation: The presence of microscopic yolk sac tumor does not confer a higher risk of recurrence or worse prognosis in pediatric ovarian IT when treated appropriately. However, the increased use of chemotherapy in the YST group may have contributed to these favorable outcomes, masking intrinsic risk differences.
Expert Commentary
The findings from this large, multi-institutional collaboration provide valuable evidence to clarify the clinical uncertainty surrounding microscopic YST in ovarian immature teratoma among children and adolescents. Historically, the presence of yolk sac tumor components—even microscopic—has prompted clinicians to consider intensified chemotherapy due to the recognized malignant potential of YST. This study’s results might support a more nuanced approach, balancing the risks of chemotherapy toxicity with the apparently favorable RFS observed.
Nonetheless, retrospective design limitations and potential treatment selection bias must be considered. Patients with microscopic YST were more likely to receive chemotherapy, which may have effectively controlled the more aggressive disease component, thus obscuring intrinsic differences in biological behavior. Future prospective studies or registries incorporating centralized pathology review and standardized treatment protocols would better define the natural history and optimal management strategies.
Additionally, integrating molecular and genetic analyses could elucidate pathogenetic differences between pure immature teratomas and those with yolk sac elements, guiding individualized treatment decisions. The report also highlights the importance of close monitoring of alpha fetoprotein trends during follow-up as a biomarker for early recurrence detection.
Conclusion
Immature ovarian teratomas containing microscopic yolk sac tumor foci in pediatric and adolescent patients represent a distinct subset characterized by higher-grade and stage disease but demonstrate favorable outcomes comparable to pure immature teratomas when treated with surgery and appropriate chemotherapy. The lack of difference in recurrence-free survival between groups suggests that microscopic YST presence alone should not drive excessively aggressive treatment decisions without considering individual risk factors.
Clinical practice should incorporate multidisciplinary evaluation and individualized risk assessment, integrating pathological findings, tumor markers, and patient factors. The study underscores the need for further prospective and translational research to refine therapeutic guidelines, aiming to maximize cure rates while minimizing treatment-related morbidity in this young population.
Funding and Clinical Trials
The study was supported by collaborative efforts of the Pediatric Surgical Oncology Research Collaborative. No specific funding details or clinical trial registration were mentioned.
References
1. Rich BS, Fishbein JS, Purcell LN, et al. Immature teratoma of the ovary with microscopic yolk sac tumor in children and adolescents: A multi-institutional study. Gynecol Oncol. 2026 Jul 8;211:125-131. PMID: 42419003.
2. Nasioudis D, Frey MK, Holcomb K, Polotsky AJ. Management and outcomes of immature ovarian teratomas: A National Cancer Database study. Gynecol Oncol. 2019;153(3):499-504.
3. Gershenson DM. Management of ovarian germ cell tumors. J Clin Oncol. 2007;25(20):2938-2943.
4. Billmire DF, Sandstedt B, Schwarz K, Geiger JD. Germ cell tumors in children and adolescents: current perspectives. Surg Oncol. 2004;13(3-4):135-141.
5. Pashankar FD, Koert J, Amer K, et al. Elevated alpha-fetoprotein level predicting recurrence in ovarian yolk sac tumors. J Pediatr Hematol Oncol. 2013;35(7):e289-e292.